Literature DB >> 33922695

A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient.

Caterina Peraldo-Neia1, Annamaria Massa2, Francesca Vita3, Marco Basiricò2,3, Chiara Raggi4, Paola Bernabei5, Paola Ostano1, Laura Casorzo6, Mara Panero6, Francesco Leone7, Giuliana Cavalloni2, Massimo Aglietta2,3.   

Abstract

Chemotherapy resistance is a relevant clinical issue in tumor treatment, in particular in biliary tract carcinoma (BTC), for which there are no effective therapies, neither in the first nor in the second line. The development of chemoresistant cell lines as experimental models to investigate the mechanisms of resistance and identify alternative druggable pathways is mandatory. In BTC, in which genetics and biological behavior depend on the etiology, ethnicity, and anatomical site of origin, the creation of models that better recapitulate these characteristics is even more crucial. Here we have established and characterized an intrahepatic cholangiocarcinoma (iCCA) cell line derived from an Italian patient, called 82.3. Cells were isolated from a patient-derived xenograft (PDX) and, after establishment, immunophenotypic, biological, genetic, molecular characteristics, and tumorigenicity in vivo in NOD/SCID mice were investigated. 82.3 cells exhibited epithelial morphology and cell markers (EPCAM, CK7, and CK19); they also expressed different cancer stem markers (CD44, CD133, CD49b, CD24, Stro1, PAX6, FOXA2, OCT3/4), α-fetoprotein and under anchorage-independent and serum-free conditions were capable of originating cholangiospheres. The population doubling time was approximately 53 h. In vitro, they demonstrated a poor ability to migrate; in vivo, 82.3 cells retained their tumorigenicity, with a long latency period (16 weeks). Genetic identity using DNA fingerprinting analysis revealed 16 different loci, and the cell line was characterized by a complex hyperdiploid karyotype. Furthermore, 82.3 cells showed cross-resistance to gemcitabine, 5-fluorouracil, carboplatin, and oxaliplatin; in fact, their genetic profile showed that 60% of genes (n = 168), specific for drug resistance and related to the epithelial-mesenchymal transition, were deregulated in 82.3 cells compared to a control iCCA cell line sensitive to chemotherapeutics. RNA sequencing analysis revealed the enrichment for genes associated with epithelial to mesenchymal transition (EMT), vasculature development, and extracellular matrix (ECM) remodeling, underlining an aggressive phenotype. In conclusion, we have created a new iCCA cell line of Caucasian origin: this could be exploited as a preclinical model to study drug resistance mechanisms and to identify alternative therapies to improve the prognosis of this tumor type.

Entities:  

Keywords:  intrahepatic cholangiocarcinoma; new cell line; patient-derived in vitro model

Year:  2021        PMID: 33922695     DOI: 10.3390/cancers13092051

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  24 in total

1.  Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.

Authors:  Naminatsu Takahara; Yousuke Nakai; Hiroyuki Isayama; Takashi Sasaki; Kei Saito; Hiroki Oyama; Sachiko Kanai; Tatsunori Suzuki; Tatsuya Sato; Ryunosuke Hakuta; Kazunaga Ishigaki; Tsuyoshi Takeda; Tomotaka Saito; Suguru Mizuno; Hirofumi Kogure; Minoru Tada; Kazuhiko Koike
Journal:  Invest New Drugs       Date:  2018-10-15       Impact factor: 3.850

2.  Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.

Authors:  Nora Schweitzer; Martha M Kirstein; Anna-Maria Kratzel; Young-Seon Mederacke; Mareike Fischer; Michael P Manns; Arndt Vogel
Journal:  Liver Int       Date:  2019-03-18       Impact factor: 5.828

3.  Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.

Authors:  J W Valle; J Furuse; M Jitlal; S Beare; N Mizuno; H Wasan; J Bridgewater; T Okusaka
Journal:  Ann Oncol       Date:  2013-12-18       Impact factor: 32.976

4.  Role of AhR in regulating cancer stem cell-like characteristics in choriocarcinoma.

Authors:  Chenchun Wu; Shuran Yu; Qianxia Tan; Peng Guo; Huining Liu
Journal:  Cell Cycle       Date:  2018-10-18       Impact factor: 4.534

5.  Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma.

Authors:  Takamichi Ishii; Kentaro Yasuchika; Hirofumi Suemori; Norio Nakatsuji; Iwao Ikai; Shinji Uemoto
Journal:  Cancer Lett       Date:  2010-02-10       Impact factor: 8.679

6.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.

Authors:  Zhiwei Wang; Yiwei Li; Dejuan Kong; Sanjeev Banerjee; Aamir Ahmad; Asfar Sohail Azmi; Shadan Ali; James L Abbruzzese; Gary E Gallick; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 7.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

8.  Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.

Authors:  Thomas Walter; Anne M Horgan; Mairead McNamara; Liz McKeever; Trisha Min; David Hedley; Stefano Serra; Monika K Krzyzanowska; Eric Chen; Helen Mackay; Ronald Feld; Malcolm Moore; Jennifer J Knox
Journal:  Eur J Cancer       Date:  2012-09-01       Impact factor: 9.162

9.  Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study.

Authors:  Zeyuan Qiang; Wenhua Zhang; Shuai Jin; Kunfu Dai; Yuting He; Lianyuan Tao; Haibo Yu
Journal:  Ann Hepatol       Date:  2020-08-22       Impact factor: 2.400

10.  Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia‑inducible factor 1α‑mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation.

Authors:  Jesús Valencia-Cervantes; Sara Huerta-Yepez; Guillermo Aquino-Jarquín; Sara Rodríguez-Enríquez; Daniel Martínez-Fong; José-Antonio Arias-Montaño; Víctor Manuel Dávila-Borja
Journal:  Oncol Rep       Date:  2018-10-12       Impact factor: 3.906

View more
  2 in total

Review 1.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

2.  Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.

Authors:  Annamaria Massa; Caterina Peraldo-Neia; Francesca Vita; Chiara Varamo; Marco Basiricò; Chiara Raggi; Paola Bernabei; Jessica Erriquez; Ivana Sarotto; Francesco Leone; Serena Marchiò; Giuliana Cavalloni; Massimo Aglietta
Journal:  Front Oncol       Date:  2022-02-17       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.